Long-term effects of rivastigmine capsules in patients with traumatic brain injury

References

• Langlois JA, Rutland-Brown W, Thomas KE. Traumatic brain injury in the United States: Emergency department visits, hospitalizations, and deaths. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, Atlanta, (GA) 2006
   Google Scholar
• Thurman D, Alverson C, Dunn K, Guerrero J, Sniezek J. Traumatic brain injury in the United States: A public health perspective. Journal of Head Trauma Rehabilitation 1999; 14: 602–615
   PubMed Web of Science ®Google Scholar
• Arciniegas DB. The cholinergic hypothesis of cognitive impairment caused by traumatic brain injury. Current Psychiatry Reports 2003; 5: 391–399
   PubMedGoogle Scholar
• Dixon CE, Bao J, Bergmann JS, Johnson KM. Traumatic brain injury reduces hippocampal high-affinity [3H]choline uptake but not extracellular choline levels in rats. Neuroscience Letters 1994; 180: 127–130
   PubMed Web of Science ®Google Scholar
• Dixon CE, Ma X, Marion DW. Reduced evoked release of acetylcholine in the rodent neocortex following traumatic brain injury. Brain Research 1997; 749: 127–130
   PubMed Web of Science ®Google Scholar
• Leonard JR, Maris DO, Grady MS. Fluid percussion injury causes loss of forebrain choline acetyltransferase and nerve growth factor receptor immunoreactive cells in the rat. Journal of Neurotrauma 1994; 11: 379–392
   PubMed Web of Science ®Google Scholar
• Chen Y, Shohami E, Constantini S, Weinstock M. Rivastigmine, a brain-selective acetylcholinesterase inhibitor, ameliorates cognitive and motor deficits induced by closed-head injury in the mouse. Journal of Neurotrauma 1998; 15: 231–237
   PubMed Web of Science ®Google Scholar
• Dewar D, Graham DI. Depletion of choline acetyltransferase activity but preservation of M1 and M2 muscarinic receptor binding sites in temporal cortex following head injury: A preliminary human postmortem study. Journal of Neurotrauma 1996; 13: 181–187
   PubMed Web of Science ®Google Scholar
• Murdoch I, Perry EK, Court JA, Graham DI, Dewar D. Cortical cholinergic dysfunction after human head injury. Journal of Neurotrauma 1998; 15: 295–305
   PubMed Web of Science ®Google Scholar
• Arciniegas D, Adler L, Topkoff J, Cawthra E, Filley CM, Reite M. Attention and memory dysfunction after traumatic brain injury: Cholinergic mechanisms, sensory gating, and a hypothesis for further investigation. Brain Injury 1999; 13: 1–13
   PubMed Web of Science ®Google Scholar
• Salmond CH, Chatfield DA, Menon DK, Pickard JD, Sahakian BJ. Cognitive sequelae of head injury: involvement of basal forebrain and associated structures. Brain 2005; 128: 189–200
   PubMed Web of Science ®Google Scholar
• Arciniegas DB, Silver JM. Pharmacotherapy of posttraumatic cognitive impairments. Behavioural Neurology 2006; 17: 25–42
   PubMed Web of Science ®Google Scholar
• Silver JM, Koumaras B, Chen M, Mirski D, Potkin SG, Reyes P, Warden D, Harvey PD, Arciniegas D, Katz DI, et al. Effects of rivastigmine on cognitive function in patients with traumatic brain injury. Neurology 2006; 67: 748–755
   PubMed Web of Science ®Google Scholar
• Lezak MD. Neuropsychological assessment3rd. Oxford University Press, New York 1995
   Google Scholar
• Shapiro A, Benedict R, Schretlen D, Brandt J. Construct and concurrent validity of the Hopkins Verbal Learning Test-revised. Clinical Neuropsychology 1999; 13: 348–358
   PubMed Web of Science ®Google Scholar
• Exelon (rivastigmine tartrate) capsules [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, NJ 2000
   Google Scholar
• Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. International Journal of Geriatric Psychopharmacology 1998; 1: 55–65
   Google Scholar
• Rosler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. British Medical Journal 1999; 318: 633–638
   PubMed Web of Science ®Google Scholar
• Cummings J, Winblad B. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Reviews in Neurotherapy 2007; 7: 1457–1463
   PubMedGoogle Scholar
• Winblad B, Cummings J, Andreasen N, Grossberg G, Onofrj M, Sadowsky C, Zechner S, Nagel J, Laue R. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease—rivastigmine patch versus capsule. International Journal of Geriatric Psychiatry 2007; 22: 456–467
   PubMed Web of Science ®Google Scholar
• Millar K, Nicoll JA, Thornhill S, Murray GD, Teasdale GM. Long term neuropsychological outcome after head injury: Relation to APOE genotype. Journal of Neurology, Neurosurgery and Psychiatry 2003; 74: 1047–1052
   PubMed Web of Science ®Google Scholar
• Himanen L, Portin R, Isoniemi H, Helenius H, Kurki T, Tenovuo O. Longitudinal cognitive changes in traumatic brain injury: A 30-year follow-up study. Neurology 2006; 66: 187–192
   PubMed Web of Science ®Google Scholar
• Whitnall L, McMillan TM, Murray GD, Teasdale GM. Disability in young people and adults after head injury: 5–7 year follow up of a prospective cohort study. Journal of Neurology, Neurosurgery and Psychiatry 2006; 77: 640–645
   PubMed Web of Science ®Google Scholar
• Wood RL, Rutterford NA. Long-term effect of head trauma on intellectual abilities: A 16-year outcome study. Journal of Neurology, Neurosurgery and Psychiatry 2006; 77: 1180–1184
   PubMed Web of Science ®Google Scholar
• Zhang L, Plotkin RC, Wang G, Sandel ME, Lee S. Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Archives of Physical Medicine and Rehabilitation 2004; 85: 1050–1055
   PubMed Web of Science ®Google Scholar